Across 44 oncology brand launches ZoomRx has tracked from pre-launch through Month 24, one metric measured before a single prescription was written consistently separated the brands that went on to lead their market from the ones that never caught up: aided awareness on Day 1. Top performers launched with an average of 75% aided awareness among target HCPs. Below-norm brands launched with 55%. ZoomRx's analysis calls this a 25-point pre-launch awareness advantage, and it is built entirely before approval - through disease education, congress presence, and KOL engagement that starts 18 to 24 months out.
That gap does not close. It tracks nearly parallel from Day 1 through Month 48, and by Month 24 it shows up as a 58% gap in Most Often Used (MOU) status between top performers and below-norm brands. The brands that win a launch are, in a measurable sense, already ahead of the brands that lose it before either one has shipped a single script.
Aided awareness is HCP recognition of a brand when it's named or prompted, as opposed to unaided (spontaneous) awareness or Top-of-Mind Awareness (TOMA), the first brand a physician recalls without any prompt at all. Aided awareness is typically the fastest of the three to build through promotion, which is exactly why ZoomRx's dataset treats Day-1 aided awareness as a clean, comparable starting line across brands: it reflects how much groundwork was laid before launch, not how the launch itself performed.
ZoomRx's longitudinal tracking shows that top performers don't wait for launch day to start building awareness, they arrive with it already built. The 75%/55% Day-1 split is the clearest evidence: two trajectories that start apart on Day 1 and stay apart, tracking nearly parallel from launch through Month 48. The gap that exists on the first day of commercial availability is, for practical purposes, the gap that persists for the next four years.
Brands that arrive at Day 1 without established HCP awareness face a prescribing deficit that compounds with every passing month, as competitors deepen their hold on physician habit. The window to influence those habits is not the first-year post-launch. It is 12 to 24 months before it. — Laggards and Leaders, ZoomRx
That pre-launch advantage is not accidental. In ZoomRx's dataset, the brands that carry it in consistently ran three sequenced awareness levers before approval: disease and unbranded education starting 18–24 months out, congress presence and data dissemination at 12–18 months, and KOL advisory boards paired with a publication strategy at 9–12 months. Each lever builds on the one before it, so that by the time branded promotion begins, physicians are already fluent in the disease conversation the brand is entering.
The Day-1 gap is where the divergence starts, but it isn't where it becomes irreversible. ZoomRx's data shows that unaided awareness trajectories separate decisively within the first three to six months post-launch and brands that fall behind in that window face a recovery curve that most of them never complete. By the time the resulting gap in MOU status becomes visible after Month 12, the outcome is largely settled.
Early momentum doesn't just matter, it compounds. Every prescription written deepens familiarity, reinforces habit, and widens the gap between leaders and lagging brands. — Laggards and Leaders, ZoomRx
This is also the window where Top-of-Mind Awareness (TOMA) becomes the most useful thing to watch. TOMA movements precede shifts in prescribing behavior, which makes it the earliest actionable signal in the funnel, visible before MOU or script data can tell you anything. A TOMA plateau in months one through three is, in ZoomRx's framing, a signal worth investigating immediately, not a footnote to revisit at the next quarterly readout.
By Month 24, the 44 brands in ZoomRx's dataset stratify into four performance archetypes, defined by brand penetration ranking at that point: Top Performers (≥80th percentile), Above Average (50th–80th), Below Average (20th–50th), and Below Norm (<20th percentile). Which archetype a brand becomes is, per the analysis, largely decided by decisions made before and during the first six months.
|
Top Performer |
Above Average |
Below Average |
Below Norm |
|
≥80th percentile |
50th–80th |
20th–50th |
<20th percentile |
|
Awareness building began 18–24 months pre-approval |
Began 9–12 months pre-approval |
Began 3–6 months pre-approval |
Began at or after launch |
Top Performers combine strong clinical differentiation with sustained pre-launch investment, HCPs arrive at launch already convinced, not still evaluating. Below Norm brands typically combine weak clinical differentiation with little or no pre-launch activity; without an external catalyst, ZoomRx's data shows recovery from that position is rare.
ZoomRx's report includes a short self-diagnostic built around this same Day-1 metric. Whatever stage your brand is at, the question is the same: what is your current aided awareness among target HCPs? The bands below are drawn directly from ZoomRx's dataset and indicate which archetype trajectory a brand most closely resembles today.
|
Top Performer |
Above Average |
Below Average |
Below Norm |
|
Above 75% |
60–75% |
40–60% |
Below 40% or unknown |
A brand tracking above 75% aided awareness is on a Top Performer trajectory. One below 40%, or one where the number simply isn't known, sits in Below Norm territory, where ZoomRx's data shows recovery without an external catalyst is rare. The whitepaper's full self-diagnostic also asks when awareness-building began, where TOMA sits relative to MOU, and whether the conversion barrier has been formally diagnosed, useful next questions once you have your Day-1 number in hand.
The honest answer, per ZoomRx's data, is that the Day-1 gap and the Month-24 gap are the same gap, just measured at different points on a curve that rarely bends. Access barriers, positioning constraints, and differentiation gaps can each still be diagnosed and addressed after launch, but the earlier a brand identifies which one it's dealing with, the more of the addressable opportunity is still on the table. Identifying the right barrier at Month 3, in ZoomRx's framing, is worth more than diagnosing it at Month 12.
This is also why launch tracking that connects awareness, promotional response, and prescribing behavior in one continuous read tends to catch the inflection earlier than research that treats them as separate studies. ZoomRx's own Integrated Launch Tracking and ATU Brand Tracking are built around exactly this: tracking aided awareness, unaided awareness, and TOMA against benchmarks from comparable launches, so a plateau shows up as a signal in month one rather than a surprise in month twelve.
For a closer look at how benchmark comparisons, not just internal targets, change what a launch tracking number actually tells you, see Your Launch May Be Hitting Its Targets – But What Do the Benchmarks Say?.
The findings above are one number from a much larger dataset. For the full 44-brand analysis including all four performance archetypes, the complete self-diagnostic, and the barrier diagnostic guide, download the full report below.